Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Feb 16;9:887–900. doi: 10.2147/DDDT.S78015

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Wang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Chromatographic fingerprint analysis and cell viability assay for the Chinese herbal formula B401.

Notes: (A) HPLC fingerprint of the herbal formula B401. Characteristic peaks of B401, ie, (a) ginsenosides Rb1 (molecular formula: C₅₄H₉₂O₂₃; molecular weight: 1,109.3 g/mol; from Panax ginseng) and oleanolic acid (molecular formula: C₃₀H₄₈O₃; molecular weight: 456.7 g/mol; from Ligustri fructus), (b) formononetin (molecular formula: C₁₆H₁₂O₄; molecular weight: 268.3 g/mol; from Astragalus membranaceus), (c) 5-hydroxymethylfurfural (molecular formula: C₆H₆O₃; molecular weight: 126.1 g/mol; from Rehmannia glutinosa), (d) ferulic acid (molecular formula: C₁₀H₁₀O₄; molecular weight: 194.2 g/mol; from L. fructus), (e) wedelolactone (molecular formula: C₁₆H₁₀O₇; molecular weight: 314.3 g/mol; from Eclipta prostrata), were identified and marked at the corresponding peaks in the fingerprint. (B) Cell viabilities of RA-induced SH-SY5Y cells with glutamate treatment for 24 hours in the absence or presence of the B401 at indicated doses, or NMDA receptor antagonist, MK-801. Glutamate-treated SH-SY5Y cell viabilities were significantly increased under B401 (B401, n=6 for each B401 dose treatment) and MK-801 treatment (MK-801, n=6) individually than their control (n=6). Values are mean ± SEM (**P<0.01, *P<0.05, two-way ANOVA followed by a Student–Newman–Keuls multiple comparisons posttest).

Abbreviations: AU, arbitrary perfusion units; 5-HMF, 5-hydroxymethylfurfural; Ctrl, control; Glu, glutamate; HPLC, high-performance liquid chromatography; RA, retinoic acid; NMDA, N-methyl-d-aspartate; SEM, standard error of the mean; ANOVA, analysis of variance.